EP1163250A2 - Improved synthesis of [2.2.1]bicyclo nucleosides - Google Patents
Improved synthesis of [2.2.1]bicyclo nucleosidesInfo
- Publication number
- EP1163250A2 EP1163250A2 EP00912410A EP00912410A EP1163250A2 EP 1163250 A2 EP1163250 A2 EP 1163250A2 EP 00912410 A EP00912410 A EP 00912410A EP 00912410 A EP00912410 A EP 00912410A EP 1163250 A2 EP1163250 A2 EP 1163250A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- optionally substituted
- compound
- chloride
- methanesulfonyl
- toluenesulfonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
Definitions
- the present invention relates to a new strategy for the synthesis of [2.2.1]bicyclo nucleosides which is shorter, provides higher overall yields, and thus more cost efficient than previously known methods for synthesis of [2.2.1]bicyclo nucleosides.
- the present invention provides a novel strategy for the synthesis of [2.2.1]bicyclic nucleosides comprising the synthesis of a novel key intermediate.
- the novel strategy is demonstrated by the synthesis of (1 S, 3R, 4R, 7S)-7-hydroxy-1-hydroxymethyl-(thymin-1- yl)-2,5-dioxabicyclo[2.2.1]heptane and has easily been extended to the synthesis of [2.2.1]bicyclo nucleosides containing other nucleobases and can be further extended to other heteroatoms than oxygen in the bicycle, such as amino and thio.
- the present invention relates to a method for the synthesis of a novel intermediate of the general formula II:
- Ri is selected form optionally substituted ary d-e-alkyl), optionally substituted tetrahydropyran-2-yl, optionally substituted arylcarbonyl and optionally substituted aryl;
- each of the substituents R 2 and R 3 is independently selected from hydrogen, optionally substituted C ⁇ . 6 -alkyl, optionally substituted aryl, and optionally substituted ary Cj-e-alkyl), with the proviso that R 2 and R 3 are not both hydrogen, or R 2 and R 3 together designate C 3 . 7 -alkylene; and
- each of the substituents R 4 and R 5 independently is R'SO 2 O- wherein R' is selected from optionally substituted alkyl and optionally substituted aryl;
- said method comprising the following step:
- starting material a compound of the general formula I:
- Ri is selected form optionally substituted aryl(C ⁇ . 6 -alkyl), optionally substituted tetrahydropyran-2-yl, optionally substituted arylcarbonyl and optionally substituted aryl;
- each of the substituents R 2 and R 3 is independently selected from hydrogen, optionally substituted C ⁇ . 6 -alkyl, optionally substituted aryl, and optionally substituted aryl(C ⁇ . 6 -alkyl), with the proviso that R 2 and R 3 are not both hydrogen, or R 2 and R 3 together designate C 3 . -alkylene; and
- R'SO 2 X wherein R' is selected from optionally substituted d-e-alkyl and optionally substituted aryl, and X designates halogen.
- the present invention also relates to the compound of the general formula II as defined above.
- the present invention furthermore relates to the compound (hereinafter termed "key intermediate") of the general formula III:
- R T is selected form optionally substituted ary d-e-alkyl), optionally substituted tetrahydropyran-2-yl, optionally substituted arylcarbonyl and optionally substituted aryl;
- each of the substituents R 4 and R 5 independently is R'SO 2 O- wherein R' is selected from optionally substituted alkyl and optionally substituted aryl;
- R 6 is selected from hydrogen, optionally substituted (d-e-alky carbonyl, optionally substituted arylcarbonyl, optionally substituted ary d-e-alkyl), optionally substituted C h alky!, and tri(alkyl/aryl)silyl; and
- R 7 is selected from optionally substituted (C ⁇ e-alkyljcarbonyloxy, optionally substituted Ci.e-alkoxy, halogen, optionally substituted arylthio, optionally substituted C ⁇ -alkylthio, and optionally substituted aryloxy.
- the main advantages of the present invention comprise the following: ⁇ Obtaining the key intermediate of the general formula III ready for coupling with silylated nucleobases in very few steps from 3-0-benzyl-4-C-hydroxymethyl-1 ,2-0- isopropylidene- -D-ribofuranose.
- the present invention relates to a method for the synthesis of a novel intermediate with the general formula II:
- R- is selected from optionally substituted ary d-e-alkyl), optionally substituted tetrahydropyran-2-yl, optionally substituted arylcarbonyl and optionally substituted aryl.
- Some preferred embodiments comprise benzyl, o-, m-, and p-methylbenzyl, 2- chlorobenzyl, 4-phenylbenzyl, tetrahydropyran-2-yl, benzoyl, phenyl, among which benzyl and 4-phenylbenzyl are preferred; and
- each of the substituents R 2 and R 3 independently is selected from hydrogen, optionally substituted d-e-alkyl, optionally substituted aryl, and optionally substituted aryl(C 1 . 6 -alkyl), with the proviso that R 2 and R 3 are not both hydrogen, such as methyl, trifluoromethyl, ethyl, propyl, / ' so-propyl, butyl, /--butyl, pentyl, cyclopentyl, hexyl, cyclohexyl, phenyl, benzyl, phenylethyl, o-, m-, and p-methylbenzyl, 2-chlorobenzyl, or R 2 and R 3 together designate C 3 . 7 -alkylene, such as 1 ,3-propylene, 1 ,4-butylene, 1 ,5-pentylene; and
- each of the substituents R 4 and R 5 independently is R'SO 2 O-, wherein R' is selected from optionally substituted d_ 6 -alkyl, optionally substituted aryl, and optionally substituted aryl(d. 6 -alkyl), such as methyl, trifluoromethyl, ethyl, 2,2,2-trifluoroethyl, propyl, /so- propyl, butyl, nonafluorobutyl, pentyl, cyclopentyl, hexyl, cyclohexyl, benzyl, o-, m- orp- methylbenzyl, 2-chlorobenzyl, phenyl, o-, m- or p-bromophenyl, and p-nitrophenyl.
- R' is selected from optionally substituted d_ 6 -alkyl, optionally substituted aryl, and optionally substituted aryl(d. 6 -alky
- the substituents R 2 and R 3 independently represent hydrogen, methyl, phenyl, benzyl, phenylethyl, preferably methyl.
- the substituents R 2 and R 3 both represent methyl.
- each of the substituents R and R 5 represent methanesulfonyl, trifluoromethanesulfonyl, ethanesulfonyl, 2,2,2-trifluoroethanesulfonyl, propanesulfonyl, iso-propanesulfonyl, butanesulfonyl, nonafluorobutanesulfonyl, pentanesulfonyl, cyclopentanesulfonyl, hexanesulfonyl, cyclohexanesulfonyl, ⁇ - toluenesulfonyl, 2-chloro- ⁇ -toluenesulfonyl, o- m-, p-toluenesulfonyl, benzenesulfonyl, o-, m-, p-bromobenzenesulfonyl, and o-,
- R and R 5 represent methanesulfonyl, trifluoromethanesulfonyl, ethanesulfonyl, 2,2,2-trifluoroethanesulfonyl, butanesulfonyl, nonafluorobutanesulfonyl, ⁇ -toluenesulfonyl, p-toluenesulfonyl, benzenesulfonyl, p- bromobenzenesulfonyl, and p-nitrobenzenesulfonyl, preferably methanesulfonyl, trifluoromethanesulfonyl, p-toluenesulfonyl and p-bromobenzenesulfonyl, more preferably methanesulfonyl, and p-toluenesulfonyl, even more preferably methanesulfonyl,
- R 4 and R 5 are identical and are selected from methanesulfonyl, trifluoromethanesulfonyl, ethanesulfonyl, 2,2,2- trifluoroethanesulfonyl, butanesulfonyl, nonafluorobutanesulfonyl, ⁇ -toluenesulfonyl, p- toluenesulfonyl, benzenesulfonyl, p-bromobenzenesulfonyl, and p-nitrobenzene-sulfonyl, preferably methanesulfonyl, trifluoromethanesulfonyl, p-toluenesulfonyl and p- bromobenzenesulfonyl, more preferably methanesulfonyl, and p-toluenesulfonyl, even more
- R ⁇ R 2 and R 3 are as defined above;
- R'SO 2 X (hereinafter “sulfonyl halide(s)") wherein R' is selected from optionally substituted d. 6 -alkyl, optionally substituted aryl, and optionally substituted aryl(d.
- 6 -alkyl such as methyl, trifluoromethyl, ethyl, 2,2,2-trifluproethyl, propyl, /so-propyl, butyl, nonafluorobutyl, pentyl, cyclopentyl, hexyl, cyclohexyl, benzyl, o-, tn- or p-methylbenzyl, 2- chlorobenzyl, phenyl, o-, m- or p-bromophenyl, p-nitrophenyl, and X designates halogen, such as fluoro, chloro, bromo, and iodo.
- R represent benzyl.
- R 2 and R 3 is selected from methyl, ethyl, propyl, /so-propyl, benzyl, phenylethyl, phenyl, or R 2 and R 3 together designate 1 ,3- propylene, 1 ,4-butylene, and 1 ,5-pentylene.
- R 2 and R 3 both represent methyl.
- R T represent benzyl and R 2 and R 3 both represent methyl.
- R'SO 2 X represents sulfonyl halides, such as methanesulfonyl chloride, trifluoromethanesulfonyl chloride, ethanesulfonyl chloride, 2,2,2-trifluoroethanesulfonyl chloride, propanesulfonyl chloride, /so-propanesulfonyl chloride, butanesulfonyl chloride, nonafluorobutanesulfonyl chloride, cyclopentanesulfonyl chloride, hexanesulfonyl chloride, cyclohexanesulfonyl chloride, ⁇ -toluenesulfonyl chloride, p-toluenesulfonyl chloride, p-bromobenzenesulfonyl chloride, p- nitrobenzenesulfonyl chloride, preferably me
- the ratio between compound I and sulfonyl halide is typically in the range of 1 :2 to 1 :10, such as 1 :2-1 :5, preferably 1 :2-1 :4, more preferably 1 :2.5-1 :3.5.
- compound I may be treated with two different sulfonyl halides, R m SO 2 X and R lv SO 2 X, wherein R"' and R ⁇ v are independently selected from the group of substituents defined for R' provided that R n ⁇ and R ⁇ v do not represent the same group, and X is as defined above.
- treatment of compound I with R'"SO 2 X and R lv SO 2 X is performed in two separate steps.
- compound I is treated with R'"SO 2 X in the ratio 1 :1-1 :1.5, preferably 1 :1-1 :1.3, more preferably 1 :1.1-1 :1.2, to afford compound II, wherein R 4 or R 5 is R'"SO 2 O- and R 5 or R is hydroxyl.
- the formed compound II is treated with R lv SO 2 X in the ratio 1 :1-1 :2.5, preferably 1 :1-1 :2, more preferably 1 :1.1-1 :1.5 to afford compound II wherein R 4 is R m SO 2 O- or R lv SO 2 O- and R 5 is R lv SO 2 O- if R 4 is R'"SO 2 O- and R 5 is R m SO 2 O- and if R 4 is R lv SO 2 O-.
- reaction of compound I with the sulfonyl halide in the presence of an anhydrous base such as pyridine, 4-dimethylaminopyridine, imidazole, triethylamine, or sodium hydride, increase the overall yield of the reaction.
- anhydrous base such as pyridine, 4-dimethylaminopyridine, imidazole, triethylamine, or sodium hydride
- the treatment is performed in the presence of pyridine, imidazole, or 4-dimethylaminopyridine, preferably pyridine.
- the treatment of compound I with the sulfonyl halide typically is carried out in the presence of a solvent, such as pyridine, tetrahydrofuran, toluene, xylene, benzene, ether, ethylacetate, acetonitril, triethylamine, ⁇ /,/V-dimethylformamide, dimethylsulfoxide, dichloromethane, and 1 ,2- dichloroethane.
- a solvent such as pyridine, tetrahydrofuran, toluene, xylene, benzene, ether, ethylacetate, acetonitril, triethylamine, ⁇ /,/V-dimethylformamide, dimethylsulfoxide, dichloromethane, and 1 ,2- dichloroethane.
- the base and the solvent may be constituted by the same substance, such as pyridine.
- the treatment of compound I with sulfonyl halide is typically performed at -70°C to 40°C, such as -30°C to 40°C.
- compound I is treated with sulfonyl halide at -5°C to 30°C, preferably 0°C to 25°C.
- the present invention also relates to the compound of the general formula II as defined above.
- the present invention furthermore relates to the compound of the general formula III: wherein R ⁇ R , and R 5 are as defined above; and
- R 6 is selected from hydrogen, optionally substituted (d. 6 -alkyl)carbonyl, optionally substituted arylcarbonyl, optionally substituted aryl(d. 6 -alkyl), optionally substituted d_ 6 - alkyl, and tri-(alkyl/aryl)silyl, such as acetyl, benzoyl, m-trifluoromethylbenzoyl, benzyl, tetf-butyldimethylsilyl and ter/-butyldiphenylsilyl; and
- R 7 is selected from optionally substituted (d. 6 -alkyl)carbonyloxy, optionally substituted d. 6 -alkoxy, halogen, optionally substituted arylthio, optionally substituted d_ 6 -alkylthio, and optionally substituted aryloxy, such as acetyloxy, methoxy, ethoxy, chloride, fluoride, bromide or iodide, or -SC 6 H 5 .
- R. represents benzyl or 4-phenylbenzyl, most preferably 4-phenylbenzyl, and R and R 5 both are selected from methanesulfonyl, trifluoromethanesulfonyl, ethanesulfonyl, 2,2,2-trifluoroethanesulfonyl, butanesulfonyl, nonafluorobutanesulfonyl, ⁇ -toluenesulfonyl, p-toluenesulfonyl, benzenesulfonyl, p- bromobenzenesulfonyl, and p-nitrobenzenesulfonyl, preferably from methanesulfonyl, trifluoromethanesulfonyl, p-toluenesulfonyl and p-bromobenzenesulfonyl, more preferably methanesulfonyl, more
- R 6 is selected from acetyl, benzoyl and m- trifluoromethylbenzoyl, preferably acetyl
- R 7 is selected from acetyloxy, methoxy, ethoxy, chloride, fluroride, bromide, iodide and -SC 6 H 5 , preferably acetyloxy and methoxy, even more preferably acetyloxy.
- R represents benzyl or 4- phenylbenzyl
- R and R 5 both represent methanesulfonyl
- R 6 represents acetyl
- R 7 represents acetyloxy.
- the key intermediate with the general formula III may be coupled with suitable protected nucleobases resulting in the formation of nucleosides which undergo base-induced ring- closure to afford 2'-0,4'-C-methylene bicyclonucleosides.
- nucleosides likewise can undergo ring-closure in the presence of different amines, preferably benzylamine, and potassium thioacetate to afford the 2'- ⁇ /,4'-C-methylene- and 2'-S,4'-C-methylene analogues, respectively.
- FIG. 4 illustrates a combination of preferred embodiments for compounds the general formula III for the preparation of [2.2.1]bicyclo nucleoside derivatives of uridine, wherein R 7 is acetoxy, R 4 and R 5 are each mesylate and R 1 is the aryl substituted benzyl, phenylbenzyl (labelled compound 106 in Figure 6).
- a general synthetic route is outlines. From the known diol 1 , a critical intermediate 3, may be conveniently prepared. Using the desired nucleobase or their derivatives (such as thymine, isobutyrylguanidine, ⁇ /-acetylcytosine, 6- /-benzoyladenine, hypoxantine), ribonucleoside derivatives 4A, 4B, 4C, 4D, and 4E can be accessed. Selective protective group manipulation allows for 2,4-cyclisation and access to many LNAs. This scheme is detailed in Examples 1-7.
- the synthesis sequence comprises: a) ⁇ / 4 - acetylcytosine, BSA, TMSTf, CH 3 CN; b) LiOH, THF/H 2 O; c) Sodium benzoate, CsCO 3 , DMF; d) Pd(OH) 2 , cyclohexane, EtOH; e) i. Bz-CI, pyridine, ii. NaOH, MeOH, pyridine.
- a different protective group strategy is used and the LNA uracil derivatives 110 and 112 are accessed. This scheme is detailed in Example 11.
- hypoxanthine as nucleobase allows access to the LNA hypoxanthine derivative 25 and the LNA-adenine derivative 27. This scheme is detailed in Example 14.
- C ⁇ . 6 -alkyl means a linear, cyclic or branched hydrocarbon group having 1 to 6 carbon atoms, such as methyl, ethyl, propyl, /so-propyl, pentyl, cyclopentyl, hexyl, cyclohexyl, preferred examples of "d.
- 6 -alkyl are methyl, ethyl, propyl, /so-propyl, butyl, tert-butyl, /so-butyl, pentyl, cyclopentyl, hexyl, cyclohexyl, in particular methyl, ethyl, propyl, /so-propyl, tert-butyl, /so-butyl and cyclohexyl.
- C 3 . 7 -alkylene means a linear biradical having 3 to 7 carbon atoms, such as 1 ,3-propylene, 1 ,4-butylene, 1 ,5-pentylene, 1 ,6-hexylene, and 1 ,7- heptylene.
- alkyl in the present context, i.e. in connection with the term “alkyl”, the term “optionally substituted” means that the group in question may be substituted one or several times, preferably 1-3 times, with group(s) selected from hydroxyl, d. 6 -alkoxy, carboxyl, d. 6 - alkoxycarbonyl, d. 6 -alkylcarbonyl, formyl, aryl, aryloxycarbonyl, arylcarbonyl, heteroaryl, amino, mono- and di(C ⁇ -6-alkyl)amino, carbamoyl, mono- and di(d.
- group(s) selected from hydroxyl, d. 6 -alkoxy, carboxyl, d. 6 - alkoxycarbonyl, d. 6 -alkylcarbonyl, formyl, aryl, aryloxycarbonyl, arylcarbonyl, heteroaryl, amino, mono- and di(C ⁇ -6-alky
- hydroxyl, drete 6 -alkoxy, carboxyl, aryl, heteroaryl, amino, mono- and di(d. 6 -alkyl)amino, and halogen where aryl and heteroaryl may be substituted 1-3 times with d. -alkyl, d. 4 -alkoxy, nitro, cyano, amino or halogen.
- Aryl and heteroaryl may be substituted as specifically describe below for "optionally substituted aryl and heteroaryl".
- aryl means a fully or partially aromatic carbocyclic ring or ring system, such as phenyl, naphthyl, 1 ,2,3,4-tetrahydronaphthyl, anthracyl, phenanthracyl, pyrenyl, benzopyrenyl, fluorenyl and xanthenyl, among which phenyl is a preferred example.
- heteroaryl groups examples include oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrrolyl, imidazolyl, pyrazolyl, pyridinyl, pyrazinyl, pyridazinyl, piperidinyl, coumaryl, furyl, quinolyl, benzothiazolyl, benzotriazolyl, benzodiazolyl, benzooxozolyl, phthalazinyl, phthalanyl, triazolyl, tetrazolyl, isoquinolyl, acridinyl, carbazolyl, dibenzazepinyl, indolyl, benzopyrazolyl, phenoxazonyl.
- aryl and “heteroaryl”
- optionally substituted means that the group in question may be substituted one or several times, preferably 1-5 times, in particular 1-3 times with group(s) selected from hydroxyl (which when present in an enol system may be represented in the tautomeric keto form), d.
- 6 -alkyl, d-e-alkoxy, oxo (which may be represented in the tautomeric enol form), carboxyl, Ci-e-alkoxycarbonyl, d_ 6 -alkylcarbonyl, formyl, aryl, aryloxy, aryloxy- carbonyl, arylcarbonyl, heteroaryl, amino, mono- and di(C ⁇ _ 6 -alkyl)amino; carbamoyl, mono- and d d-e-alkyOaminocarbonyl, amino-d. 6 -alkyl-aminocarbonyl, mono- and di(d. 6 -alkyl)amino-d.
- tri(alkyl/aryl)silyl means a silyl group substituted with 0-3 alkyl groups and/or 0-3 aryl groups, with the provision that the total number of alkyl and aryl groups is 3, selected from trimethylsilyl, allyldimethylsilyl, dimethylphenylsilyl, diphenylmethylsilyl, isopropyldimethylsilyl, tert-butyldimethylsilyl, and tert- butyldiphenylsilyl,
- Halogen includes fluoro, chloro, bromo, and iodo.
- nucleobase covers naturally occurring nucleobases as well as non-naturally occurring nucleobases. It should be clear to the person skilled in the art that various nucleobases which previously have been considered “non-naturally occurring” have subsequently been found in nature. Thus, “nucleobase” includes not only the known purine and pyrimidine heterocycles, but also heterocyclic analogues and tautomers thereof.
- nucleobases are adenine, guanine, thymine, cytosine, uracil, purine, xanthine, diaminopurine, ⁇ -oxo- ⁇ methyladenine, 7- deazaxanthine, 7-deazaguanine, /V./V-ethanocytosine, ⁇ . ⁇ -ethano ⁇ . ⁇ -diaminopurine, 5-methylcytosine, 5-(C 3 -C 6 )-alkynylcytosine, 5-fluorouracil, 5-bromouracil, pseudoiso- cytosine, 2-hydroxy-5-methyl-4-triazolopyridine, isocytosine, isoguanin, inosine and the "non-naturally occurring" nucleobases described in Benner et al., U.S.
- nucleobase is intended to cover every and all of these examples as well as analogues and tautomers thereof.
- Especially interesting nucleobases are adenine, guanine, thymine, cytosine, and uracil, which are considered as the naturally occurring nucleobases in relation to therapeutic and diagnostic application in humans.
- nucleoside means a glycoside of a heterocyclic base.
- nucleoside is used broadly as to include non-naturally occurring nucleosides, naturally occurring nucleosides as well as other nucleoside analogues.
- Illustrative examples of nucleosides are ribonucleosides comprising a ribose moiety as well as deoxyribonuclesides comprising a deoxyribose moiety.
- bases of such nucleosides it should be understood that this may be any of the naturally occurring bases, e.g. adenine, guanine, cytosine, thymine, and uracil, as well as any modified variants thereof or any possible unnatural bases.
- Trimethylsilyl triflate (1.8 mL, 9.4 mmol) was then added dropwise and refluxing was continued for more 2 h.
- the reaction was cooled to room temperature, diluted with dichloromethane (200 mL) and washed by saturated aqueous solution of sodium hydrogencarbonate (2 x 200 mL).
- the organic layer was dried over Na 2 SO , concentrated under reduced pressure and purified by silica gel flash chromatography using dichloromethane/methanol (98:2 v/v) as eluent to yield 2.4 g (85 %) of nucleoside (4a) as a white solid material.
- ⁇ c (CD 3 CI) 170.0 (C O), 163.7 (C-6), 150.1 (C-2), 137.9, 136.6, (C-5, Bn), 128.6, 128.5, 128.4 (Bn), 111. 8 (C-4), 92.4, 84.0, 77.9, 74.8, 73.7, 68.4, 67.5 (ribose, Bn), 37.7, 37.6 (methanesulfonyls), 20.7 (acetyl), 12.6 (CH 3 ).
- reaction mixture was neutralized by acetic acid (to pH 7), filtered through silica gel column and concentrated under reduced pressure.
- Analytical amount of compound (6b) was purified by semi-prep RP-HPLC (Nucleosil C18, 10 x 30 mm) using the same solvents as in system A.
- Compound (6b) (ca.10 mg) was dissolved in methanol, 10 % Pd/C (50 mg) and ammonium format (20 mg) were added and the mixture was refluxed for 15 min.
- Analysis of the reaction mixture in system A shown a quantitative formation of compound (7b) (retention time 4.7 min) with the same mobility as authentic compound prepared by method described earlier (Koshkin, A. A.; Singh, S. K.; Nielsen, P.; Rajwanshi, V. K.; Kumar, R.; Meldgaard, M.; Olsen, C. E.; Wengel, J., Tetrahedron 1998, 54(14), 3607).
- ⁇ c (CDCI 3 ) 180.2 (CHCO), 154.8, 148.2, 147.7 (guanine), 137.9, 136.3, (guanine, Bn), 128.3, 127.6, 127.5 (Bn), 120.5 (guanine), 88.2, 85.2, 76.9, 72.1 , 71.3, 56.7 (ribose, Bn), 34.8 (CHCO), 18.9 (CH 3 CH).
- reaction mixture was diluted with dichloromethane (100 mL), washed with saturated aqueous NaHCO 3 (200 mL), concentrated under reduced pressure, and the product was purified by column silica gel chromatography (1 to 3 % of methanol/dichloromethane as eluent). Yield 3.5 g (53 %) of compound 17 as yellow foam.
- Nucleoside 108 (1.56 g, 3.11 mmol) was dissolved in dry ⁇ /, ⁇ /-dimethylacetamide (40 mL) under N 2 , and sodium benzoate (2.25 g, 15.61 mmol) was added. The slurry was heated to 100°C and stirred at this temperature for 3 hours. The mixture was filtered through a thin pad of CeliteTM, which was washed with plenty of CH 2 CI 2 . The combined filtrates were diluted with CH 2 CI 2 (150 mL) and washed with saturated
- nucleoside 109 To a stirred solution of nucleoside 109 (910 mg, 1.73 mmol) in dry CH 2 CI 2 (20 mL) under N 2 was added anhydrous FeCI 3 (Aldrich, 99.99 + %, 560 mg, 3.45 mmol). The reaction mixture (initially a clear red-brown solution. After ca.30 min. a brown precipitate was observed, which changed to green-blue after another 30 min.) was stirred at room temperature for 2.5 hours. The reaction was quenched by addition of water (10 mL) and diluted with CH 2 CI 2 . The mixture was filtrated through a thin pad of CeliteTM, that was washed with CH 2 CI 2 and MeOH.
- anhydrous FeCI 3 Aldrich, 99.99 + %, 560 mg, 3.45 mmol
- nucleoside 4C To a stirred suspension of bismesylate 3 (13.0g, 25.47 mmol) and N 4 -acetylcytosine (6.24 g, 40.75 mmol) in dry CH 3 CN (250 mL) under N 2 was added N,0- bis(trimethylsilyl)acetamide (25.0 mL, 102.25 mmol, Fluka 97 %). The mixture was heated to 40 °C and stirred at this temperature until a clear solution resulted (ca.20 min.). The mixture was cooled to room temperature and trimethylsilyl triflate (10.0 mL, 55.34 mmol) was added dropwise.
- the resulting reaction mixture was heated to reflux and stirred at this temperature for 2.5 hours.
- the mixture was cooled in an ice bath and saturated aqueous NaHC0 3 (100 mL) was carefully added.
- the formed solid material was filtrated off and washed with CH 2 CI 2 (60 mL). Layers were separated and the aqueous layer was extracted with CH 2 CI 2 (100 mL).
- the combined organic layers were diluted with CH 2 CI 2 (250 mL) and washed with saturated aqueous NaHC0 3 (2 x 100 mL), dried (MgS0 4 ) and evaporated under reduced pressure.
- Nucleoside 4C (5.6 g, 9.28 mmol) was dissolved in THF/H 2 0 (90 mL, 1/1, v/v), and LiOH ⁇ 2 0 (2.34 g, 55.76 mmol) was added. The reaction mixture was stirred at room temperature for 4 hours and the mixture was concentrated under reduced pressure to ca.50 mL. The residue was partitioned between CH 2 CI 2 (200 mL) and saturated aqueous NaHC0 3 (100 mL). The bright yellow aqueous layer was extracted with CH 2 CI 2 (2 x 100 mL).
- the reaction mixture was cooled to room temperature and concentrated under reduced pressure.
- the residue was partitioned between CH 2 CI 2 (250 mL) and saturated aqueous NaHC0 3 (250 mL).
- the aqueous layer was extracted with CH 2 CI 2 (2 x 150 mL) and the combined organic layers were washed with brine (100 mL), dried (Na 2 S0 4 ) and evaporated under reduced pressure.
- Nucleoside 6aC (390 mg, 1.08 mmol, crude material), was co-evaporated with dry pyridine (3x) and re-dissolved in dry pyridine (5.0 mL) under N 2 .
- Benzoyl chloride (0.25 mL, 2.15 mmol) was added dropwise and the reaction mixture was stirred at room temperature for 60 min. The mixture was cooled in an ice bath and MeOH (20
- 6-N-Benzoyladenine (11.02 g.; 46.1 mmol) was dried in vacuo overnight.
- ⁇ c (DMSO-d 6 /CDCI 3 ): 165.5, 151.5, 150.8, 150.1, 140.6, 136.6, 133.1, 132.0, 128.2, 128.0, 127.9, 127.6, 127.3, 124.5, 86.0, 84.8, 78.1, 76.6, 71.8, 71.7, 64.7, 37.1.
- ⁇ c (DMSO-d 6 ) 158.2, 156.6, 147.3, 146.1, 144.8, 137.1, 135.5, 135.3, 129.8, 127.9, 127.7, 126.8, 124.6, 113.3 (DMT, hypoxantine), 87.1, 85.6, 79.3, 71.8, 70.5, 59.9 (ribose), 55.1 (DMT).
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK00912410T DK1163250T3 (en) | 1999-03-24 | 2000-03-24 | Improved synthesis of [2.2.1] bicyclonucleosides |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA199900407 | 1999-03-24 | ||
DK40799 | 1999-03-24 | ||
DK200000099 | 2000-01-21 | ||
DKPA200000099 | 2000-01-21 | ||
PCT/DK2000/000141 WO2000056746A2 (en) | 1999-03-24 | 2000-03-24 | Improved synthesis of [2.2.1]bicyclo nucleosides |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1163250A2 true EP1163250A2 (en) | 2001-12-19 |
EP1163250B1 EP1163250B1 (en) | 2006-07-12 |
Family
ID=26063935
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00912410A Expired - Lifetime EP1163250B1 (en) | 1999-03-24 | 2000-03-24 | Improved synthesis of ¬2.2.1|bicyclo nucleosides |
Country Status (10)
Country | Link |
---|---|
US (1) | US6639059B1 (en) |
EP (1) | EP1163250B1 (en) |
JP (1) | JP4768132B2 (en) |
AT (1) | ATE332909T1 (en) |
AU (1) | AU3418800A (en) |
DE (1) | DE60029314T2 (en) |
DK (1) | DK1163250T3 (en) |
ES (1) | ES2269113T3 (en) |
IL (1) | IL145496A0 (en) |
WO (1) | WO2000056746A2 (en) |
Families Citing this family (190)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6734291B2 (en) * | 1999-03-24 | 2004-05-11 | Exiqon A/S | Synthesis of [2.2.1]bicyclo nucleosides |
WO2000056746A2 (en) * | 1999-03-24 | 2000-09-28 | Exiqon A/S | Improved synthesis of [2.2.1]bicyclo nucleosides |
US6962906B2 (en) | 2000-03-14 | 2005-11-08 | Active Motif | Oligonucleotide analogues, methods of synthesis and methods of use |
EP1263773A4 (en) | 2000-03-14 | 2005-08-31 | Active Motif | Oligonucleotide analogues, methods of synthesis and methods of use |
WO2002028875A2 (en) * | 2000-10-04 | 2002-04-11 | Cureon A/S | Improved synthesis of purine locked nucleic acid analogues |
EP1446412B1 (en) | 2001-09-04 | 2012-03-07 | Exiqon A/S | Novel lna compositions and uses thereof |
US20030166282A1 (en) * | 2002-02-01 | 2003-09-04 | David Brown | High potency siRNAS for reducing the expression of target genes |
EP1470148B1 (en) | 2002-02-01 | 2012-07-18 | Life Technologies Corporation | Double-stranded oligonucleotides |
US20060009409A1 (en) | 2002-02-01 | 2006-01-12 | Woolf Tod M | Double-stranded oligonucleotides |
SI2264172T1 (en) | 2002-04-05 | 2017-12-29 | Roche Innovation Center Copenhagen A/S | Oligomeric compounds for the modulation of hif-1alpha expression |
US20040248094A1 (en) * | 2002-06-12 | 2004-12-09 | Ford Lance P. | Methods and compositions relating to labeled RNA molecules that reduce gene expression |
EP1532271A4 (en) * | 2002-06-12 | 2006-10-18 | Ambion Inc | Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference |
US20040219565A1 (en) | 2002-10-21 | 2004-11-04 | Sakari Kauppinen | Oligonucleotides useful for detecting and analyzing nucleic acids of interest |
EP2112229A3 (en) | 2002-11-25 | 2009-12-02 | Sequenom, Inc. | Methods for identifying risk of breast cancer and treatments thereof |
US7713738B2 (en) | 2003-02-10 | 2010-05-11 | Enzon Pharmaceuticals, Inc. | Oligomeric compounds for the modulation of survivin expression |
PT1592793E (en) | 2003-02-10 | 2009-09-30 | Santaris Pharma As | Oligomeric compounds for the modulation of survivin expression |
ES2332178T5 (en) | 2003-03-21 | 2014-02-04 | Santaris Pharma A/S | Small RNA interference analogs (siRNA) |
CN1833034B (en) | 2003-06-20 | 2014-04-16 | 埃克斯魁恩公司 | Probes, libraries and kits for analysis of mixtures of nucleic acids and methods for constructing the same |
US7622453B2 (en) * | 2003-12-23 | 2009-11-24 | Santaris Pharma A/S | Oligomeric compounds for the modulation of Bcl-2 |
US8192937B2 (en) | 2004-04-07 | 2012-06-05 | Exiqon A/S | Methods for quantification of microRNAs and small interfering RNAs |
EP1776482A2 (en) | 2004-06-30 | 2007-04-25 | Applera Corporation | Log-linear amplification |
EP1809765A2 (en) * | 2004-11-04 | 2007-07-25 | Roche Diagnostics GmbH | Classification of acute myeloid leukemia |
NZ555644A (en) | 2004-11-09 | 2009-04-30 | Santaris Pharma As | Potent LNA oligonucleotides for the inhibition of HIF-1A expression |
NZ555645A (en) | 2004-11-09 | 2009-08-28 | Santaris Pharma As | LNA oligonucleotides and the treatment of cancer |
US7842794B2 (en) | 2004-12-17 | 2010-11-30 | Roche Molecular Systems, Inc. | Reagents and methods for detecting Neisseria gonorrhoeae |
US20060142228A1 (en) * | 2004-12-23 | 2006-06-29 | Ambion, Inc. | Methods and compositions concerning siRNA's as mediators of RNA interference |
WO2006069584A2 (en) | 2004-12-29 | 2006-07-06 | Exiqon A/S | NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF microRNAs AND THEIR TARGET mRNAs |
US7838502B2 (en) | 2005-05-06 | 2010-11-23 | University Of Massachusetts Medical School | Compositions and methods to modulate H. influenzae pathogenesis |
US8067208B2 (en) | 2005-06-30 | 2011-11-29 | Roche Molecular Systems, Inc. | Probes and methods for hepatitis C virus typing using multidimensional probe analysis |
EP3000480A1 (en) | 2005-12-01 | 2016-03-30 | ProNAi Therapeutics, Inc. | Cancer therapies and pharmaceutical compositions used therein |
CN101437933B (en) | 2005-12-28 | 2013-11-06 | 斯克里普斯研究所 | Natural antisense and non-coding RNA transcripts as drug targets |
US7296313B2 (en) * | 2006-01-13 | 2007-11-20 | Matthaus Hense | Inflatable knee pillow having thin profile and foldability when deflated |
DK2002004T3 (en) | 2006-03-23 | 2015-11-30 | Roche Innovation Ct Copenhagen As | LITTLE INTERNAL SEGMENTED INTERFERENCE RNA |
CA2649045C (en) | 2006-04-03 | 2019-06-11 | Santaris Pharma A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
EP3431602A1 (en) | 2006-04-03 | 2019-01-23 | Roche Innovation Center Copenhagen A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
EP2035831B1 (en) | 2006-06-30 | 2013-08-14 | Applied Biosystems, LLC | Methods of analyzing binding interactions |
US8188255B2 (en) | 2006-10-20 | 2012-05-29 | Exiqon A/S | Human microRNAs associated with cancer |
EP2090665A2 (en) | 2006-10-20 | 2009-08-19 | Exiqon A/S | Novel human microRNAs associated with cancer |
EP2118118B1 (en) | 2007-01-19 | 2017-09-27 | Exiqon A/S | Mediated cellular delivery of lna oligonucleotides |
WO2008113830A1 (en) | 2007-03-22 | 2008-09-25 | Santaris Pharma A/S | Rna antagonist compounds for the inhibition of apo-b100 expression |
DK2149605T3 (en) | 2007-03-22 | 2013-09-30 | Santaris Pharma As | Short RNA antagonist compounds to modulate the desired mRNA |
US7884194B2 (en) | 2007-06-06 | 2011-02-08 | Avi Biopharma Inc. | Soluble HER2 and HER3 splice variant proteins, splice-switching oligonucleotides, and their use in the treatment of disease |
US8097422B2 (en) | 2007-06-20 | 2012-01-17 | Salk Institute For Biological Studies | Kir channel modulators |
US8299237B2 (en) | 2007-08-30 | 2012-10-30 | Hadasit Medical Research Services & Development Ltd. | Nucleic acid sequences comprising NF-κB binding site within O(6)-methylguanine-DNA-methyltransferase (MGMT) promoter region and uses thereof for the treatment of cancer and immune-related disorders |
EP2195428B1 (en) | 2007-09-19 | 2013-12-11 | Applied Biosystems, LLC | SiRNA SEQUENCE-INDEPENDENT MODIFICATION FORMATS FOR REDUCING OFF-TARGET PHENOTYPIC EFFECTS IN RNAi, AND STABILIZED FORMS THEREOF |
US8440637B2 (en) | 2007-10-04 | 2013-05-14 | Santaris Pharma A/S | Combination treatment for the treatment of hepatitis C virus infection |
EP2212437A4 (en) | 2007-11-07 | 2011-09-28 | Univ British Columbia | Microfluidic device and method of using same |
EP4053546A1 (en) | 2007-12-06 | 2022-09-07 | Genalyte, Inc. | Device and method for performing label-free monitoring of processes. |
EP2620511B1 (en) | 2008-01-17 | 2018-02-28 | Sequenom, Inc. | Single molecule nucleic acid sequence analysis processes |
US8361980B2 (en) | 2008-03-07 | 2013-01-29 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of microRNA related diseases |
US10150990B2 (en) | 2008-04-21 | 2018-12-11 | Roche Molecular Systems, Inc. | Ribonucleotide tag nucleic acid detection |
CA2635187A1 (en) | 2008-06-05 | 2009-12-05 | The Royal Institution For The Advancement Of Learning/Mcgill University | Oligonucleotide duplexes and uses thereof |
US20090312196A1 (en) | 2008-06-13 | 2009-12-17 | Codexis, Inc. | Method of synthesizing polynucleotide variants |
HUE029228T2 (en) | 2008-06-13 | 2017-02-28 | Codexis Inc | Method of synthesizing polynucleotide variants |
US8492357B2 (en) | 2008-08-01 | 2013-07-23 | Santaris Pharma A/S | Micro-RNA mediated modulation of colony stimulating factors |
US8476013B2 (en) | 2008-09-16 | 2013-07-02 | Sequenom, Inc. | Processes and compositions for methylation-based acid enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses |
US8962247B2 (en) | 2008-09-16 | 2015-02-24 | Sequenom, Inc. | Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non invasive prenatal diagnoses |
KR101770435B1 (en) | 2008-10-03 | 2017-09-05 | 큐알엔에이, 인크. | Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoproteina1 |
JP5656853B2 (en) | 2008-10-27 | 2015-01-21 | ジェナリーテ, インコーポレイテッド | Biosensor based on optical exploration and detection |
MX358603B (en) | 2008-12-04 | 2018-08-28 | Curna Inc | Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene. |
WO2010065792A2 (en) | 2008-12-04 | 2010-06-10 | Curna, Inc. | Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo |
EP2370581B1 (en) | 2008-12-04 | 2016-08-03 | CuRNA, Inc. | Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf |
US8206929B2 (en) | 2009-01-07 | 2012-06-26 | Roche Molecular Systems, Inc. | Nucleic acid amplification with allele-specific suppression of sequence variants |
US8940501B2 (en) | 2009-01-30 | 2015-01-27 | Whitehead Institute For Biomedical Research | Methods for ligation and uses thereof |
DK2396038T3 (en) | 2009-02-12 | 2016-02-01 | Curna Inc | TREATMENT OF BRAIN-DERIVATED NEUROTROPHIC FACTOR- (BDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTION TO BDNF |
MX2011009751A (en) | 2009-03-16 | 2011-09-29 | Opko Curna Llc | Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2. |
MX2011009752A (en) | 2009-03-17 | 2011-09-29 | Opko Curna Llc | Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1. |
WO2010118243A2 (en) | 2009-04-08 | 2010-10-14 | Genentech, Inc. | Use of il-27 antagonists to treat lupus |
ES2599979T3 (en) | 2009-04-24 | 2017-02-06 | Roche Innovation Center Copenhagen A/S | Pharmaceutical compositions for the treatment of HCV patients who do not respond to interferon |
JP5883782B2 (en) | 2009-05-06 | 2016-03-15 | クルナ・インコーポレーテッド | Treatment of lipid transport metabolism gene-related diseases by suppression of natural antisense transcripts on lipid transport metabolism genes |
ES2609655T3 (en) | 2009-05-06 | 2017-04-21 | Curna, Inc. | Treatment of diseases related to tristetraproline (TTP) by inhibition of natural antisense transcript for TTP |
KR101742334B1 (en) | 2009-05-08 | 2017-06-01 | 큐알엔에이, 인크. | Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family |
CN102575251B (en) | 2009-05-18 | 2018-12-04 | 库尔纳公司 | The relevant disease of the reprogramming factor is treated by inhibiting the natural antisense transcript for the reprogramming factor |
WO2010135695A2 (en) | 2009-05-22 | 2010-11-25 | Curna, Inc. | TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) and INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3 |
JP5960049B2 (en) | 2009-05-28 | 2016-08-02 | クルナ・インコーポレーテッド | Treatment of antiviral gene-related diseases by suppression of natural antisense transcripts against antiviral genes |
ES2620960T3 (en) | 2009-06-16 | 2017-06-30 | Curna, Inc. | Treatment of diseases related to a collagen gene by inhibiting a natural antisense transcript to a collagen gene |
US8951981B2 (en) | 2009-06-16 | 2015-02-10 | Curna, Inc. | Treatment of paraoxonase 1 (PON1) related diseases by inhibition of natural antisense transcript to PON1 |
KR101807323B1 (en) | 2009-06-24 | 2017-12-08 | 큐알엔에이, 인크. | Ttreatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2 |
CN102482672B (en) | 2009-06-26 | 2016-11-09 | 库尔纳公司 | By suppressing the natural antisense transcript treatment Down syndrome gene-associated diseases of Down syndrome gene |
US8563528B2 (en) | 2009-07-21 | 2013-10-22 | Santaris Pharma A/S | Antisense oligomers targeting PCSK9 |
CA2768947C (en) | 2009-07-24 | 2018-06-19 | Opko Curna, Llc | Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt) |
US9234199B2 (en) | 2009-08-05 | 2016-01-12 | Curna, Inc. | Treatment of insulin gene (INS) related diseases by inhibition of natural antisense transcript to an insulin gene (INS) |
CA2770104C (en) | 2009-08-11 | 2019-03-19 | Opko Curna, Llc | Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq) |
US8409802B2 (en) | 2009-08-14 | 2013-04-02 | Roche Molecular Systems, Inc. | Format of probes to detect nucleic acid differences |
JP5943836B2 (en) | 2009-08-21 | 2016-07-05 | カッパーアールエヌエー,インコーポレイテッド | Treatment of CHIP-related diseases by inhibition of natural antisense transcripts on 'HSP70 interacting protein C-terminus' (CHIP) |
CN102482671B (en) | 2009-08-25 | 2017-12-01 | 库尔纳公司 | IQGAP relevant diseases are treated by suppressing the natural antisense transcript of ' gtpase activating protein containing IQ die bodys ' (IQGAP) |
EP2480669B1 (en) | 2009-09-25 | 2017-11-08 | CuRNA, Inc. | Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity |
WO2011084455A2 (en) | 2009-12-16 | 2011-07-14 | Opko Curna, Llc. | Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1 |
WO2011087789A2 (en) | 2009-12-22 | 2011-07-21 | Becton, Dickinson And Company | Methods for the detection of microorganisms |
ES2577017T3 (en) | 2009-12-22 | 2016-07-12 | Sequenom, Inc. | Procedures and kits to identify aneuploidy |
KR101793753B1 (en) | 2009-12-23 | 2017-11-03 | 큐알엔에이, 인크. | Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2 |
CN102869776B (en) | 2009-12-23 | 2017-06-23 | 库尔纳公司 | HGF relevant diseases are treated by suppressing the natural antisense transcript of HGF (HGF) |
RU2615450C2 (en) | 2009-12-29 | 2017-04-04 | Курна, Инк. | Treating diseases associated with nuclear respiratory factor 1 (nrf1) by inhibition of natural antisense transcript to nrf1 |
KR101853508B1 (en) | 2009-12-29 | 2018-06-20 | 큐알엔에이, 인크. | TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63 |
RU2616283C2 (en) | 2009-12-31 | 2017-04-13 | Курна, Инк. | Treatment of diseases associated with substrate of insulin receptor 2 (irs2) by inhibition of natural antisense transcript to irs2 |
ES2664605T3 (en) | 2010-01-04 | 2018-04-20 | Curna, Inc. | Treatment of diseases related to interferon regulatory factor 8 (irf8) by inhibition of the natural antisense transcript to the irf8 gene |
WO2011085066A2 (en) | 2010-01-06 | 2011-07-14 | Curna, Inc. | Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene |
CN102803493B (en) | 2010-01-11 | 2018-07-31 | 库尔纳公司 | SHBG relevant diseases are treated by inhibiting the natural antisense transcript of sex hormone binding globulin (SHBG) |
WO2011091390A2 (en) | 2010-01-25 | 2011-07-28 | Opko Curna, Llc | Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1 |
KR101838308B1 (en) | 2010-02-22 | 2018-03-13 | 큐알엔에이, 인크. | Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1 |
WO2011105902A2 (en) | 2010-02-23 | 2011-09-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Antagonists of complement component 8-beta (c8-beta) and uses thereof |
WO2011105900A2 (en) | 2010-02-23 | 2011-09-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Antagonists of complement component 8-alpha (c8-alpha) and uses thereof |
WO2011105901A2 (en) | 2010-02-23 | 2011-09-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Antagonists of complement component 9 (c9) and uses thereof |
WO2011123745A2 (en) | 2010-04-02 | 2011-10-06 | Opko Curna Llc | Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3 |
JP5978203B2 (en) | 2010-04-09 | 2016-08-24 | カッパーアールエヌエー,インコーポレイテッド | Treatment of fibroblast growth factor (FGF21) fibroblast growth factor FGF21) related diseases by inhibition of natural antisense transcripts against FGF21 |
WO2011133931A1 (en) | 2010-04-22 | 2011-10-27 | Genentech, Inc. | Use of il-27 antagonists for treating inflammatory bowel disease |
ES2465948T3 (en) | 2010-04-30 | 2014-06-09 | Exiqon A/S | In situ hybridization procedure and buffer |
RU2018110641A (en) | 2010-05-03 | 2019-02-27 | Курна, Инк. | TREATMENT OF DISEASES ASSOCIATED WITH SIRTUIN (SIRT) BY INHIBITING A NATURAL ANTISENSE TRANSCRIPT TO SIRTUIN (SIRT) |
TWI586356B (en) | 2010-05-14 | 2017-06-11 | 可娜公司 | Treatment of par4 related diseases by inhibition of natural antisense transcript to par4 |
WO2011150007A2 (en) | 2010-05-26 | 2011-12-01 | Opko Curna Llc | Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra |
US8895528B2 (en) | 2010-05-26 | 2014-11-25 | Curna, Inc. | Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1 |
US9771579B2 (en) | 2010-06-23 | 2017-09-26 | Curna, Inc. | Treatment of sodium channel, voltage-gated, alpha subunit (SCNA) related diseases by inhibition of natural antisense transcript to SCNA |
ES2663598T3 (en) | 2010-07-14 | 2018-04-16 | Curna, Inc. | Treatment of diseases related to the large disc homolog (dlg) by inhibiting the natural antisense transcript to dlg |
GB201012418D0 (en) | 2010-07-23 | 2010-09-08 | Santaris Pharma As | Process |
JP6106085B2 (en) | 2010-08-24 | 2017-03-29 | サーナ・セラピューティクス・インコーポレイテッドSirna Therapeutics,Inc. | Single-stranded RNAi agent containing an internal non-nucleic acid spacer |
ES2640755T3 (en) | 2010-10-06 | 2017-11-06 | Curna, Inc. | Treatment of diseases related to Sialidase 4 (neu4) by inhibition of the natural antisense transcript to the neu4 gene |
CA2815212A1 (en) | 2010-10-22 | 2012-04-26 | Curna, Inc. | Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua |
US9921165B2 (en) | 2010-11-05 | 2018-03-20 | Genalyte, Inc. | Optical analyte detection systems and methods of use |
WO2012068340A2 (en) | 2010-11-18 | 2012-05-24 | Opko Curna Llc | Antagonat compositions and methods of use |
CA2818824A1 (en) | 2010-11-23 | 2012-05-31 | Joseph Collard | Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog |
US20120208189A1 (en) | 2011-01-14 | 2012-08-16 | Life Technologies Corporation | Methods for isolation, identification, and quantification of mirnas |
ES2653247T3 (en) | 2011-06-09 | 2018-02-06 | Curna, Inc. | Treatment of frataxin-related diseases (FXN) by inhibiting the natural antisense transcript to the FXN gene |
EP2753317B1 (en) | 2011-09-06 | 2020-02-26 | CuRNA, Inc. | TREATMENT OF DISEASES RELATED TO ALPHA SUBUNITS OF SODIUM CHANNELS, VOLTAGE-GATED (SCNxA) WITH SMALL MOLECULES |
US9605313B2 (en) | 2012-03-02 | 2017-03-28 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
WO2013138251A1 (en) | 2012-03-12 | 2013-09-19 | The Board Of Trustes Of The University Of Illinois | Optical analyte detection systems with magnetic enhancement and methods of use |
CN110438125A (en) | 2012-03-15 | 2019-11-12 | 科纳公司 | By inhibiting the natural antisense transcript of brain derived neurotrophic factor (BDNF) to treat BDNF related disease |
AU2013266461A1 (en) | 2012-05-21 | 2014-12-11 | The Scripps Research Institute | Ribosomal polynucleotides and related expression systems |
US9920361B2 (en) | 2012-05-21 | 2018-03-20 | Sequenom, Inc. | Methods and compositions for analyzing nucleic acid |
CA2878979C (en) | 2012-07-13 | 2021-09-14 | Sequenom, Inc. | Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses |
CA2890725A1 (en) | 2012-11-05 | 2014-05-08 | Pronai Therapeutics, Inc. | Methods of using biomarkers for the treatment of cancer by modulation of bcl2|expression |
EP2943570B1 (en) | 2013-01-14 | 2018-01-03 | Pierfrancesco Tassone | Inhibitors of mirnas 221 and 222 for anti-tumor activity in multiple myeloma |
US10086093B2 (en) | 2013-02-28 | 2018-10-02 | The General Hospital Corporation | miRNA profiling compositions and methods of use |
US11060145B2 (en) | 2013-03-13 | 2021-07-13 | Sequenom, Inc. | Methods and compositions for identifying presence or absence of hypermethylation or hypomethylation locus |
US9828629B2 (en) | 2013-03-15 | 2017-11-28 | Roche Molecular Systems, Inc. | Nucleic acid target identification by structure based probe cleavage |
US9983206B2 (en) | 2013-03-15 | 2018-05-29 | The Board Of Trustees Of The University Of Illinois | Methods and compositions for enhancing immunoassays |
DK3013959T3 (en) | 2013-06-27 | 2020-02-17 | Roche Innovation Ct Copenhagen As | ANTISENSE OLIGOMERS AND CONJUGATES TARGETED PCSK9 |
JP2016537965A (en) | 2013-10-11 | 2016-12-08 | ジェネンテック, インコーポレイテッド | NSP4 inhibitors and methods of use |
CN105722977A (en) | 2013-10-30 | 2016-06-29 | 绿色生活生物技术有限责任公司 | Pathogenesis quantification systems and treatment methods for citrus greening blight |
WO2015075166A1 (en) | 2013-11-22 | 2015-05-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treatment of a bacterial infection |
US9637791B2 (en) | 2013-12-20 | 2017-05-02 | Roche Molecular Systems, Inc. | Multiplexed nucleic acid target identification by strucutre based probe cleavage |
WO2015118407A2 (en) | 2014-01-29 | 2015-08-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Oligonucleotides and methods for inhibiting or reducing bacterial biofilms |
WO2015138774A1 (en) | 2014-03-13 | 2015-09-17 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
EA201790642A1 (en) | 2014-09-18 | 2017-09-29 | Ти Юниверсити Оф Бритиш Коламбиа | ALLEL-SPECIFIC THERAPY FOR HAPLOTYPES OF HANTINGTON'S DISEASE |
CA2963288A1 (en) | 2014-10-03 | 2016-04-07 | Cold Spring Harbor Laboratory | Targeted augmentation of nuclear gene output |
TWI740546B (en) * | 2014-10-29 | 2021-09-21 | 美商基利科學股份有限公司 | Methods for the preparation of ribosides |
US11136390B2 (en) | 2015-06-12 | 2021-10-05 | Alector Llc | Anti-CD33 antibodies and methods of use thereof |
WO2016201389A2 (en) | 2015-06-12 | 2016-12-15 | Alector Llc | Anti-cd33 antibodies and methods of use thereof |
CN115960235A (en) | 2015-08-28 | 2023-04-14 | 艾利妥 | anti-SIGLEC-7 antibodies and methods of use thereof |
WO2017060731A1 (en) | 2015-10-09 | 2017-04-13 | University Of Southampton | Modulation of gene expression and screening for deregulated protein expression |
CN116003596A (en) | 2015-10-29 | 2023-04-25 | 艾利妥 | anti-SIGLEC-9 antibodies and methods of use thereof |
EP3390636B1 (en) | 2015-12-14 | 2021-05-19 | Cold Spring Harbor Laboratory | Antisense oligomers for treatment of dravet syndrome |
US11096956B2 (en) | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
WO2017205506A1 (en) | 2016-05-24 | 2017-11-30 | Emory University | Particles with rna cleaving nucleobase polymers and uses for managing inflammatory disorders |
EP3494219A1 (en) | 2016-08-03 | 2019-06-12 | Aalborg Universitet | ANTISENSE OLIGONUCLEOTIDES (ASOs) DESIGNED TO INHIBIT IMMUNE CHECKPOINT PROTEINS |
US11147249B2 (en) | 2016-12-08 | 2021-10-19 | Alector Llc | Siglec transgenic mice and methods of use thereof |
US11359014B2 (en) | 2017-05-16 | 2022-06-14 | Alector Llc | Anti-siglec-5 antibodies and methods of use thereof |
KR20200033798A (en) | 2017-08-03 | 2020-03-30 | 알렉터 엘엘씨 | Anti-CD33 antibodies and methods of use |
PT3673080T (en) | 2017-08-25 | 2023-12-06 | Stoke Therapeutics Inc | Antisense oligomers for treatment of conditions and diseases |
EP3697904A1 (en) | 2017-10-17 | 2020-08-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combination treatment for cystic fibrosis |
US11470827B2 (en) | 2017-12-12 | 2022-10-18 | Alector Llc | Transgenic mice expressing human TREM proteins and methods of use thereof |
CN112334776A (en) | 2018-06-21 | 2021-02-05 | 豪夫迈·罗氏有限公司 | Hybrid all-LNA oligonucleotides |
AU2019310597A1 (en) | 2018-07-27 | 2021-03-11 | Alector Llc | Anti-siglec-5 antibodies and methods of use thereof |
CN110818748A (en) * | 2018-08-07 | 2020-02-21 | 广州市锐博生物科技有限公司 | Synthesis method of nucleoside compound and intermediate thereof |
US20210308215A1 (en) | 2018-09-21 | 2021-10-07 | President And Fellows Of Harvard College | Methods and compositions for treating diabetes, and methods for enriching mrna coding for secreted proteins |
EP3880837A1 (en) | 2018-11-16 | 2021-09-22 | F. Hoffmann-La Roche AG | Streptavidin-coated solid phases with a member of a binding pair |
EP3980554A1 (en) | 2019-06-07 | 2022-04-13 | F. Hoffmann-La Roche AG | Hybridizing all-lna oligonucleotides |
WO2021005223A1 (en) | 2019-07-10 | 2021-01-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of epilepsy |
IT201900017234A1 (en) | 2019-09-25 | 2021-03-25 | Int Centre For Genetic Engineering And Biotechnology | Anti-miRNA for the treatment of leiomyoma |
WO2021074657A1 (en) | 2019-10-17 | 2021-04-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combination treatment for cystic fibrosis |
US20230016983A1 (en) | 2019-11-19 | 2023-01-19 | lNSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) | Antisense oligonucleotides and thier use for the treatment of cancer |
IL298063A (en) | 2020-05-11 | 2023-01-01 | Stoke Therapeutics Inc | Opa1 antisense oligomers for treatment of conditions and diseases |
CA3179226A1 (en) | 2020-05-29 | 2021-12-02 | Tomas Cihlar | Remdesivir treatment methods |
WO2021243271A2 (en) | 2020-05-29 | 2021-12-02 | Front Range Biosciences, Inc. | Methods and compositions for pathogen detection in plants |
WO2022006019A1 (en) | 2020-06-29 | 2022-01-06 | Front Range Biosciences, Inc. | Characterization of cannabis cultivars based on terpene synthase gene profiles |
CA3177613A1 (en) | 2020-07-10 | 2022-04-13 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for treating epilepsy |
JP2024506371A (en) | 2021-02-12 | 2024-02-13 | メランド ファーマシューティカルズ,インコーポレイテッド | Agents, compositions and methods for treating hypoxia and ischemia related disorders |
CN117440815A (en) | 2021-03-26 | 2024-01-23 | 神经微核糖核酸治疗有限公司 | MicroRNA-134 inhibitors |
EP4313074A1 (en) | 2021-03-26 | 2024-02-07 | Neumirna Therapeutics ApS | Microrna-27b inhibitors |
EP4347824A1 (en) | 2021-06-04 | 2024-04-10 | Neumirna Therapeutics ApS | Antisense oligonucleotides targeting adenosine kinase |
KR20240046879A (en) | 2021-08-17 | 2024-04-11 | 한국과학기술원 | Antisense oligonucleotide targeting CAV3.1 gene and use thereof |
WO2023021184A1 (en) | 2021-08-19 | 2023-02-23 | Neumirna Therapeutics Aps | Antisense oligonucleotides targeting adenosine kinase |
US20230159930A1 (en) | 2021-11-19 | 2023-05-25 | Sanegene Bio Usa Inc. | Double stranded rna targeting angiopoietin-like 3 (angptl-3) and methods of use thereof |
WO2023104812A1 (en) | 2021-12-09 | 2023-06-15 | F. Hoffmann-La Roche Ag | Mass based detection of pcr amplicons |
WO2023152369A1 (en) | 2022-02-14 | 2023-08-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Nucleic acid mir-9 inhibitor for the treatment of cystic fibrosis |
US20240002857A1 (en) | 2022-05-09 | 2024-01-04 | Sanegene Bio Usa Inc. | Double stranded rna targeting 17-beta hydroxysteroiddehydrogenase 13 (hsd17b13) and methods of use thereof |
WO2024017990A1 (en) | 2022-07-21 | 2024-01-25 | Institut National de la Santé et de la Recherche Médicale | Methods and compositions for treating chronic pain disorders |
US20240052348A1 (en) | 2022-08-05 | 2024-02-15 | Sanegene Bio Usa Inc. | Double stranded rna targeting angiotensinogen (agt) and methods of use thereof |
EP4332239A1 (en) | 2022-08-30 | 2024-03-06 | Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l. | Mir-based assay for gastro-entero-pancreatic neuroendocrine tumor diagnosis and prognosis |
WO2024081954A2 (en) | 2022-10-14 | 2024-04-18 | Sanegene Bio Usa Inc. | Small interfering rna targeting c3 and uses thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2103918T3 (en) | 1991-10-17 | 1997-10-01 | Ciba Geigy Ag | BICYCLE NUCLEOSIDES, OLIGONUCLEOTIDES, PROCEDURE FOR THEIR OBTAINING AND INTERMEDIATE PRODUCTS. |
JPH0680688A (en) * | 1992-09-03 | 1994-03-22 | Asahi Breweries Ltd | 4'-methylnucleoside derivative |
EP0963997B1 (en) * | 1996-11-18 | 2003-02-19 | Takeshi Imanishi | Novel nucleotide analogues |
JP3756313B2 (en) | 1997-03-07 | 2006-03-15 | 武 今西 | Novel bicyclonucleosides and oligonucleotide analogues |
JP4236812B2 (en) | 1997-09-12 | 2009-03-11 | エクシコン エ/エス | Oligonucleotide analogues |
ATE465168T1 (en) * | 1999-03-18 | 2010-05-15 | Exiqon As | XYLO-LNA ANALOGUE |
WO2000056746A2 (en) * | 1999-03-24 | 2000-09-28 | Exiqon A/S | Improved synthesis of [2.2.1]bicyclo nucleosides |
NZ514348A (en) * | 1999-05-04 | 2004-05-28 | Exiqon As | L-ribo-LNA analogues |
AU5428900A (en) * | 1999-06-22 | 2001-01-09 | Sankyo Company Limited | Novel 3'-4' bridged nucleosides and oligonucleotide analogues |
-
2000
- 2000-03-24 WO PCT/DK2000/000141 patent/WO2000056746A2/en active IP Right Grant
- 2000-03-24 IL IL14549600A patent/IL145496A0/en unknown
- 2000-03-24 DE DE60029314T patent/DE60029314T2/en not_active Expired - Lifetime
- 2000-03-24 JP JP2000606607A patent/JP4768132B2/en not_active Expired - Lifetime
- 2000-03-24 US US09/534,769 patent/US6639059B1/en not_active Expired - Lifetime
- 2000-03-24 DK DK00912410T patent/DK1163250T3/en active
- 2000-03-24 EP EP00912410A patent/EP1163250B1/en not_active Expired - Lifetime
- 2000-03-24 ES ES00912410T patent/ES2269113T3/en not_active Expired - Lifetime
- 2000-03-24 AU AU34188/00A patent/AU3418800A/en not_active Abandoned
- 2000-03-24 AT AT00912410T patent/ATE332909T1/en not_active IP Right Cessation
Non-Patent Citations (1)
Title |
---|
See references of WO0056746A2 * |
Also Published As
Publication number | Publication date |
---|---|
ATE332909T1 (en) | 2006-08-15 |
WO2000056746A3 (en) | 2001-10-18 |
ES2269113T3 (en) | 2007-04-01 |
IL145496A0 (en) | 2002-06-30 |
DK1163250T3 (en) | 2006-11-13 |
DE60029314D1 (en) | 2006-08-24 |
EP1163250B1 (en) | 2006-07-12 |
WO2000056746A2 (en) | 2000-09-28 |
US6639059B1 (en) | 2003-10-28 |
JP4768132B2 (en) | 2011-09-07 |
AU3418800A (en) | 2000-10-09 |
DE60029314T2 (en) | 2007-07-12 |
JP2002540116A (en) | 2002-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1163250B1 (en) | Improved synthesis of ¬2.2.1|bicyclo nucleosides | |
US6734291B2 (en) | Synthesis of [2.2.1]bicyclo nucleosides | |
US5593975A (en) | Adenosine derivatives having A2 agonist activity | |
Mansuri et al. | Preparation of 1-(2, 3-dideoxy-. beta.-D-glycero-pent-2-enofuranosyl) thymine (d4T) and 2', 3'-dideoxyadenosine (ddA): general methods for the synthesis of 2', 3'-olefinic and 2', 3'-dideoxy nucleoside analogs active against HIV | |
US5446139A (en) | Purine analog nucleoside and nucleotide compounds | |
FI108643B (en) | Stereoselective glycosylation procedure for the preparation of a nucleoside enriched in beta | |
JP3142128B2 (en) | 2 ', 3'-dideoxy-2', 2'-difluoronucleosides | |
KR101279393B1 (en) | Synthesis of Protected 3'-Amino Nucleoside Monomers | |
US4900828A (en) | Intermediate compounds and an improved procedure for the synthesis of 2',3'-dideoxycytidine | |
NL9300058A (en) | 1,5-ANHYDROHEXITOL NUCLEOSIDE ANALOGA AND PHARMACEUTICAL USE THEREOF. | |
EP0342203A1 (en) | 2',3' dideoxyribofuranoxide derivatives. | |
US5744597A (en) | Stereoselective anion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides | |
CA2079796A1 (en) | Nucleoside derivatives | |
JPH06192255A (en) | Oxetanylpurine and pyrimidine analogue | |
IL88330A (en) | 2', 3'-Dideoxy-2'-Fluoronucleosides, their preparation and pharmaceutical compositions containing them. | |
KR20070073958A (en) | Difluoronucleosides and process for preparation thereof | |
EP0292101A2 (en) | Process for the preparation of 3'-azido-3'-deoxythymidine and intermediates | |
Hutchinson et al. | New potent and selective A1 adenosine receptor agonists | |
Nomura et al. | Nucleosides and nucleotides. Part 212: Practical large-scale synthesis of 1-(3-C-ethynyl-β-d-ribo-pentofuranosyl) cytosine (ECyd), a potent antitumor nucleoside. Isobutyryloxy group as an efficient anomeric leaving group in the Vorbrüggen glycosylation reaction | |
JP5091126B2 (en) | Process for the preparation of α-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl sulfonate and its use for preparing β-nucleosides | |
US5644043A (en) | 2',3'-dideoxy-2',2'-difluoronucleosides and intermediates | |
WO1997043295A1 (en) | D-pentofuranose derivatives and process for the preparation thereof | |
JP3025559B2 (en) | Adenosine derivatives | |
CN114502565A (en) | Process for producing bicyclic phosphoramidites | |
KR920004982B1 (en) | 2',3'-dideoxy-2'-fluoro-nucleostides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20010919 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL PAYMENT 20010919;LT PAYMENT 20010919;LV PAYMENT 20010919;MK PAYMENT 20010919;RO PAYMENT 20010919;SI PAYMENT 20010919 |
|
17Q | First examination report despatched |
Effective date: 20050606 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED. Effective date: 20060712 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060712 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060712 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060712 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
RTI2 | Title (correction) |
Free format text: IMPROVED SYNTHESIS OF (2.2.1)BICYCLO NUCLEOSIDES |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 60029314 Country of ref document: DE Date of ref document: 20060824 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20061212 |
|
LTIE | Lt: invalidation of european patent or patent extension |
Effective date: 20060712 |
|
ET | Fr: translation filed | ||
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2269113 Country of ref document: ES Kind code of ref document: T3 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20070413 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070326 Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070331 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20061013 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070324 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060712 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 17 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 18 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 19 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: PC2A Owner name: QIAGEN GMBH Effective date: 20190225 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PCOW Free format text: NEW ADDRESS: SKELSTEDET 16, 2950 VEDBAEK (DK) Ref country code: CH Ref legal event code: PUE Owner name: QIAGEN GMBH, DE Free format text: FORMER OWNER: EXIQON A/S, DK |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20190325 Year of fee payment: 20 Ref country code: DE Payment date: 20190321 Year of fee payment: 20 Ref country code: FR Payment date: 20190322 Year of fee payment: 20 Ref country code: CH Payment date: 20190320 Year of fee payment: 20 Ref country code: GB Payment date: 20190320 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20190320 Year of fee payment: 20 Ref country code: DK Payment date: 20190322 Year of fee payment: 20 Ref country code: SE Payment date: 20190320 Year of fee payment: 20 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 60029314 Country of ref document: DE Representative=s name: DENNEMEYER & ASSOCIATES S.A., LU Ref country code: DE Ref legal event code: R081 Ref document number: 60029314 Country of ref document: DE Owner name: QIAGEN GMBH, DE Free format text: FORMER OWNER: EXIQON A/S, VEDBAEK, DK |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E Free format text: REGISTERED BETWEEN 20190516 AND 20190522 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: PD Owner name: QIAGEN GMBH; DE Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT; FORMER OWNER NAME: EXIQON A/S Effective date: 20190627 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20190418 Year of fee payment: 20 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R071 Ref document number: 60029314 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MK Effective date: 20200323 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EUP Expiry date: 20200324 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 Expiry date: 20200323 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20200323 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: EUG |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20220104 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20200325 |